Lifevantage Corporation Common Stock (Delaware) (LFVN)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I see LifeVantage as a small seller of dietary supplements and personal-care products with modest profitability and no clear durable moat in the numbers. Revenue fell from $228.5M in fiscal 2025 to $182.6M in fiscal 2026, while net income dropped from $9.8M to $5.1M and diluted EPS from $0.75 to $0.40. The quarterly picture is uneven: fiscal Q2 2026 net income was only $276,000, though fiscal Q3 2026 recovered to $1.4M on $43.7M of revenue. FairStock's Lynch category is SLOW GROWER — Shrinking, with profit down 17.0% a year over five years and revenue down 3.7%. Financial health is mixed. Free cash flow is $6.7M, an 8.9% yield, and debt/equity is 0.29, which is reassuring. But ROCE is just 6.25%, Altman Z-Score is 0.36, and Piotroski is 5/9, suggesting weak operating quality and balance-sheet risk. Valuation does not offer a Graham-style bargain: at the 2026-10-13 close of $5.95, FairStock's P/E is 14.87, P/B is 2.22, and the Graham Number is $4.91, leaving a negative margin of safety of 21.18%. The 3.16% dividend yield and 0.76 beta may attract income and defensive investors, but a shrinking top line and volatile profits make the margin of safety thin. I would want to see revenue and earnings stabilize before calling this cheap.

In plain English: LifeVantage sells dietary supplements and skin and hair products. The business looks weak because sales and profits have fallen sharply. At the recent price of $5.95, the shares look expensive compared with recent earnings and asset value, though the company does generate cash and pays a dividend.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer